CER-002 – PPAR delta agonists
CER-002 was developed from new chemical entities that are specific agonists for human PPAR delta, a multifaceted therapeutic target with broad potential for the treatment of cardiovascular and metabolic diseases.
In preclinical models, CER-002 has demonstrated strong efficacy in elevating HDL and in halting the progression of atherosclerosis.
It was selected for clinical development from a series of small molecule compounds available to Cerenis through a licensing agreement with Nippon Chemiphar Co., Ltd.
CER-002 has completed Phase I demonstrating that the product is well tolerated and safe at all doses tested, without any serious adverse effects. Cerenis is exploring several orphan drug indication development pathways.